ReNeuron Group plc
RNUGF · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $6 |
| % Growth | 31.5% | 56.8% | -95.8% | – |
| Cost of Goods Sold | $4 | $8 | $10 | $16 |
| Gross Profit | -$4 | -$8 | -$9 | -$10 |
| % Margin | -742.1% | -1,902% | -3,597.7% | -169.3% |
| R&D Expenses | $4 | $8 | $10 | $16 |
| G&A Expenses | $1 | $1 | $1 | $2 |
| SG&A Expenses | $1 | $1 | $4 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$2 | -$6 | -$10 | $2 |
| Operating Expenses | $3 | $4 | $4 | $21 |
| Operating Income | -$7 | -$11 | -$13 | -$14 |
| % Margin | -1,342.5% | -2,786.1% | -5,024.9% | -237.6% |
| Other Income/Exp. Net | $0 | $0 | -$0 | $1 |
| Pre-Tax Income | -$7 | -$11 | -$13 | -$14 |
| Tax Expense | -$1 | -$1 | -$2 | -$2 |
| Net Income | -$5 | -$10 | -$11 | -$11 |
| % Margin | -1,020.4% | -2,404.2% | -4,415.2% | -188.2% |
| EPS | -0.095 | -0.17 | -0.29 | -0.35 |
| % Growth | 44.3% | 41.4% | 17.1% | – |
| EPS Diluted | -0.095 | -0.17 | -0.29 | -0.35 |
| Weighted Avg Shares Out | 57 | 57 | 39 | 33 |
| Weighted Avg Shares Out Dil | 57 | 57 | 39 | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$11 | -$13 | -$13 |
| % Margin | -1,201.9% | -2,657.3% | -5,057.6% | -221% |